東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Exploiting Signaling Signatures in Triple-Negative Breast Cancer to Identify Targetable Vulnerabilities.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Exploiting Signaling Signatures in Triple-Negative Breast Cancer to Identify Targetable Vulnerabilities./
作者:	Hillis, Alissandra L.
面頁冊數:	1 online resource (234 pages)
附註:	Source: Dissertations Abstracts International, Volume: 84-12, Section: B.
Contained By:	Dissertations Abstracts International84-12B.
標題:	Cellular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30423018click for full text (PQDT)
ISBN:	9798379603403

Exploiting Signaling Signatures in Triple-Negative Breast Cancer to Identify Targetable Vulnerabilities.
Hillis, Alissandra L.

Exploiting Signaling Signatures in Triple-Negative Breast Cancer to Identify Targetable Vulnerabilities. - 1 online resource (234 pages)

Source: Dissertations Abstracts International, Volume: 84-12, Section: B.

Thesis (Ph.D.)--Harvard University, 2023.

Includes bibliographical references

Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease with the worst five-year survival rate of all breast cancer subtypes. The standard of care for TNBC is chemotherapy, but not all patients respond to chemotherapy, and responders often recur with chemotherapy-resistant disease. There are limited targeted therapy options for TNBC, in part, because tumor heterogeneity has precluded the identification of druggable drivers of disease. However, TNBC has several common genetic alterations, including hyperactivation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, epidermal growth factor receptor (EGFR) overexpression, and protein tyrosine phosphatase (PTP) loss. In this thesis, we exploit the signaling signatures of TNBC, using two distinct approaches, to identify targetable vulnerabilities.In the first approach, we performed a genome-wide negative selection CRISPR/Cas9 screen with PI3K/AKT inhibitors in TNBC cells and identified synthetic lethality between PI3K/AKT pathway inhibition and disruption of cholesterol homeostasis genes. AKT inhibitors synergized with statins, cholesterol biosynthesis inhibitors, to induce apoptotic cell death in TNBC cells but not in estrogen receptor (ER)- positive breast cancer cells or non-tumorigenic breast epithelial cells. We showed that TNBC cells are hypersensitive to statins due to dysregulated cholesterol homeostasis, which prevents statin-induced upregulation of HMG-CoA reductase (HMGCR), a rate-limiting enzyme in cholesterol biosynthesis. This work proposes a novel combination treatment strategy for TNBC, combining a potent statin, pitavastatin, with AKT inhibition. In the second approach, we characterized the metabolic tyrosine phosphoproteome in TNBC, driven by EGFR overexpression and PTP loss. We performed parallel phosphoproteomics and metabolomics in triple-negative, non-tumorigenic mammary epithelial cells, followed by an integrated analysis of the two datasets. This analysis identified both previously characterized tyrosine phosphorylation (pTyr) sites and uncharacterized pTyr sites on metabolic enzymes. We developed a CRISPR interference (CRISPRi) system to further define the functional consequences of the uncharacterized pTyr sites. By combining metabolomics with phosphoproteomics, we propose a method to globally characterize the functional significance of the metabolic tyrosine phosphoproteome, which can be used to identify functionally relevant targets in TNBC. Altogether, this thesis identifies a novel targeted therapy combination for TNBC and proposes multiple methods by which to functionally characterize TNBC and identify druggable targets.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798379603403Subjects--Topical Terms:

3172791
Cellular biology.
Subjects--Index Terms:

CancerIndex Terms--Genre/Form:

542853
Electronic books.

Exploiting Signaling Signatures in Triple-Negative Breast Cancer to Identify Targetable Vulnerabilities.
LDR:04066nmm a2200397K 4500 001 2363000
005 20231109104729.5
006 m o d
007 cr mn ---uuuuu
008 241011s2023 xx obm 000 0 eng d
020 $a 9798379603403
035 $a (MiAaPQ)AAI30423018
035 $a AAI30423018
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Hillis, Alissandra L. $3 3703743
245 1 0 $a Exploiting Signaling Signatures in Triple-Negative Breast Cancer to Identify Targetable Vulnerabilities.
264 0 $c 2023
300 $a 1 online resource (234 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 84-12, Section: B.
500 $a Advisor: Toker, Alex.
502 $a Thesis (Ph.D.)--Harvard University, 2023.
504 $a Includes bibliographical references
520 $a Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease with the worst five-year survival rate of all breast cancer subtypes. The standard of care for TNBC is chemotherapy, but not all patients respond to chemotherapy, and responders often recur with chemotherapy-resistant disease. There are limited targeted therapy options for TNBC, in part, because tumor heterogeneity has precluded the identification of druggable drivers of disease. However, TNBC has several common genetic alterations, including hyperactivation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, epidermal growth factor receptor (EGFR) overexpression, and protein tyrosine phosphatase (PTP) loss. In this thesis, we exploit the signaling signatures of TNBC, using two distinct approaches, to identify targetable vulnerabilities.In the first approach, we performed a genome-wide negative selection CRISPR/Cas9 screen with PI3K/AKT inhibitors in TNBC cells and identified synthetic lethality between PI3K/AKT pathway inhibition and disruption of cholesterol homeostasis genes. AKT inhibitors synergized with statins, cholesterol biosynthesis inhibitors, to induce apoptotic cell death in TNBC cells but not in estrogen receptor (ER)- positive breast cancer cells or non-tumorigenic breast epithelial cells. We showed that TNBC cells are hypersensitive to statins due to dysregulated cholesterol homeostasis, which prevents statin-induced upregulation of HMG-CoA reductase (HMGCR), a rate-limiting enzyme in cholesterol biosynthesis. This work proposes a novel combination treatment strategy for TNBC, combining a potent statin, pitavastatin, with AKT inhibition. In the second approach, we characterized the metabolic tyrosine phosphoproteome in TNBC, driven by EGFR overexpression and PTP loss. We performed parallel phosphoproteomics and metabolomics in triple-negative, non-tumorigenic mammary epithelial cells, followed by an integrated analysis of the two datasets. This analysis identified both previously characterized tyrosine phosphorylation (pTyr) sites and uncharacterized pTyr sites on metabolic enzymes. We developed a CRISPR interference (CRISPRi) system to further define the functional consequences of the uncharacterized pTyr sites. By combining metabolomics with phosphoproteomics, we propose a method to globally characterize the functional significance of the metabolic tyrosine phosphoproteome, which can be used to identify functionally relevant targets in TNBC. Altogether, this thesis identifies a novel targeted therapy combination for TNBC and proposes multiple methods by which to functionally characterize TNBC and identify druggable targets.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Cellular biology. $3 3172791
650 4 $a Oncology. $3 751006
650 4 $a Biochemistry. $3 518028
653 $a Cancer
653 $a Cholesterol
653 $a Heterogeneous disease
653 $a Phosphoproteome
653 $a Metabolic tyrosine
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0379
690 $a 0992
690 $a 0487
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a Harvard University. $b Medical Sciences. $3 3181716
773 0 $t Dissertations Abstracts International $g 84-12B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30423018 $z click for full text (PQDT)